A detailed history of Baillie Gifford & CO transactions in Alnylam Pharmaceuticals, Inc. stock. As of the latest transaction made, Baillie Gifford & CO holds 4,887,000 shares of ALNY stock, worth $1.24 Billion. This represents 1.03% of its overall portfolio holdings.

Number of Shares
4,887,000
Previous 6,032,656 18.99%
Holding current value
$1.24 Billion
Previous $1.47 Billion 8.3%
% of portfolio
1.03%
Previous 1.16%

Shares

30 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 05, 2024

SELL
$233.81 - $287.01 $268 Million - $329 Million
-1,145,656 Reduced 18.99%
4,887,000 $1.34 Billion
Q2 2024

Jul 25, 2024

SELL
$143.31 - $247.0 $84.7 Million - $146 Million
-590,921 Reduced 8.92%
6,032,656 $1.47 Billion
Q1 2024

May 01, 2024

SELL
$146.51 - $198.2 $50.3 Million - $68.1 Million
-343,520 Reduced 4.93%
6,623,577 $990 Million
Q4 2023

Jan 26, 2024

SELL
$151.41 - $196.57 $181 Million - $235 Million
-1,196,042 Reduced 14.65%
6,967,097 $1.33 Billion
Q3 2023

Nov 13, 2023

SELL
$170.77 - $211.65 $39.1 Million - $48.5 Million
-229,077 Reduced 2.73%
8,163,139 $1.45 Billion
Q2 2023

Jul 28, 2023

SELL
$185.01 - $212.05 $45.7 Million - $52.4 Million
-246,925 Reduced 2.86%
8,392,216 $1.59 Billion
Q1 2023

May 03, 2023

SELL
$182.66 - $235.53 $140 Million - $181 Million
-768,730 Reduced 8.17%
8,639,141 $1.73 Billion
Q4 2022

Jan 24, 2023

SELL
$185.53 - $241.31 $19.8 Million - $25.8 Million
-106,887 Reduced 1.12%
9,407,871 $2.24 Billion
Q3 2022

Oct 27, 2022

SELL
$138.54 - $232.0 $62.9 Million - $105 Million
-453,676 Reduced 4.55%
9,514,758 $1.9 Billion
Q2 2022

Aug 08, 2022

SELL
$120.42 - $169.29 $20.6 Million - $29 Million
-171,295 Reduced 1.69%
9,968,434 $1.45 Billion
Q1 2022

May 05, 2022

SELL
$127.18 - $173.91 $60.7 Million - $83 Million
-477,022 Reduced 4.49%
10,139,729 $1.66 Billion
Q4 2021

Jan 20, 2022

BUY
$159.56 - $209.29 $32.1 Million - $42.1 Million
200,967 Added 1.93%
10,616,751 $1.8 Billion
Q3 2021

Oct 19, 2021

BUY
$169.75 - $207.73 $32.4 Million - $39.7 Million
190,925 Added 1.87%
10,415,784 $1.97 Billion
Q2 2021

Aug 02, 2021

BUY
$128.63 - $176.89 $19.3 Million - $26.5 Million
149,896 Added 1.49%
10,224,859 $1.73 Billion
Q1 2021

May 06, 2021

BUY
$126.83 - $175.69 $120 Million - $166 Million
942,541 Added 10.32%
10,074,963 $1.42 Billion
Q4 2020

Feb 10, 2021

BUY
$122.97 - $147.0 $29.6 Million - $35.4 Million
240,934 Added 2.71%
9,132,422 $1.19 Billion
Q3 2020

Nov 12, 2020

BUY
$121.19 - $165.49 $29.4 Million - $40.2 Million
242,810 Added 2.81%
8,891,488 $1.29 Billion
Q2 2020

Aug 12, 2020

BUY
$104.21 - $156.44 $24.7 Million - $37.1 Million
236,909 Added 2.82%
8,648,678 $1.28 Billion
Q1 2020

May 08, 2020

BUY
$93.12 - $133.99 $21 Million - $30.2 Million
225,046 Added 2.75%
8,411,769 $916 Million
Q4 2019

Feb 10, 2020

SELL
$74.51 - $124.23 $3.67 Million - $6.12 Million
-49,251 Reduced 0.6%
8,186,723 $943 Million
Q3 2019

Nov 07, 2019

BUY
$70.9 - $87.82 $143 Million - $178 Million
2,022,504 Added 32.55%
8,235,974 $662 Million
Q2 2019

Aug 08, 2019

BUY
$65.86 - $92.79 $34.8 Million - $49.1 Million
528,966 Added 9.31%
6,213,470 $451 Million
Q1 2019

May 01, 2019

BUY
$72.76 - $93.45 $68.2 Million - $87.6 Million
937,654 Added 19.75%
5,684,504 $0
Q4 2018

Feb 14, 2019

BUY
$62.67 - $88.33 $17.8 Million - $25.1 Million
284,024 Added 6.36%
4,746,850 $346 Million
Q3 2018

Nov 13, 2018

BUY
$87.52 - $122.67 $20.2 Million - $28.3 Million
230,945 Added 5.46%
4,462,826 $391 Million
Q2 2018

Jul 17, 2018

BUY
$88.31 - $107.8 $35.1 Million - $42.9 Million
397,668 Added 10.37%
4,231,881 $417 Million
Q1 2018

May 10, 2018

BUY
$115.92 - $148.54 $25.9 Million - $33.2 Million
223,199 Added 6.18%
3,834,213 $457 Million
Q4 2017

Feb 13, 2018

BUY
$114.49 - $139.98 $23.5 Million - $28.8 Million
205,622 Added 6.04%
3,611,014 $459 Million
Q3 2017

Oct 20, 2017

SELL
$72.53 - $118.27 $1.88 Million - $3.07 Million
-25,924 Reduced 0.76%
3,405,392 $400 Million
Q2 2017

Aug 10, 2017

BUY
N/A
3,431,316
3,431,316 $274 Million

Others Institutions Holding ALNY

About ALNYLAM PHARMACEUTICALS, INC.


  • Ticker ALNY
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 123,028,000
  • Market Cap $31.1B
  • Description
  • Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. The company's pipeline of investigational RNAi therapeutics focuses on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system...
More about ALNY
Track This Portfolio

Track Baillie Gifford & CO Portfolio

Follow Baillie Gifford & CO and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Baillie Gifford & CO, based on Form 13F filings with the SEC.

News

Stay updated on Baillie Gifford & CO with notifications on news.